|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM237433648 |
| 003 |
DE-627 |
| 005 |
20250216222754.0 |
| 007 |
tu |
| 008 |
231224s2014 xx ||||| 00| ||chi c |
| 028 |
5 |
2 |
|a pubmed25n0791.xml
|
| 035 |
|
|
|a (DE-627)NLM237433648
|
| 035 |
|
|
|a (NLM)24739719
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a chi
|
| 100 |
1 |
|
|a Wei, Qiqi
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A cross-sectional survey of coagulation factor VIII inhibitor in children with hemophilia A
|
| 264 |
|
1 |
|c 2014
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.10.2014
|
| 500 |
|
|
|a Date Revised 07.06.2016
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a OBJECTIVE: To study the current situation of coagulation factor VIII (FVIII) inhibitor development in children with hemophilia A (HA) through a cross-sectional survey, and to explore the risk factors of inhibitor development in order to provide evidence for further prevention and management strategies
|
| 520 |
|
|
|a METHOD: The clinical data of outpatients with hemophilia A in Beijing Children's Hospital seen from November 2012 to May 2013 were collected, FVIII inhibitor was screened and analyzed its risk factors
|
| 520 |
|
|
|a RESULT: A total of 102 HA children were enrolled, 5 were mild cases, 32 were moderate, and 65 were severe cases; the median age on enrollment was 55.5 (3.0-200.0) months:19(18.6%) of patients had inhibitors and 9 (8.8%) had low-titer inhibitors, 10 (9.8%) had high-titer inhibitors. Receiving FVIII treatment for life-threatening bleeding (P = 0.03) ,OR 4.10 (95%CI:1.17-14.32) was a risk factor for inhibitor generation and patients within 20 exposure days have more chances of inhibitor development (P = 0.04) ,OR 3.32 (95%CI:1.02-10.86) . High and intense FVIII exposure within short term was the risk factor for high titer inhibitor development (P = 0.01) ,OR 5.25 (95%CI:1.45-21.92)
|
| 520 |
|
|
|a CONCLUSION: Intense FVIII exposure for severe hemorrhage was the risk factor of inhibitors development especially of high titer inhibitors
|
| 650 |
|
4 |
|a English Abstract
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Blood Coagulation Factor Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Factor VIII
|2 NLM
|
| 650 |
|
7 |
|a 9001-27-8
|2 NLM
|
| 700 |
1 |
|
|a Li, Gang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tang, Ling
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Zhenping
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhen, Yingzi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wu, Xinyi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Ningning
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Jishui
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yu, Guoxia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wu, Runhui
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Zhonghua er ke za zhi = Chinese journal of pediatrics
|d 1960
|g 52(2014), 2 vom: 16. Feb., Seite 99-102
|w (DE-627)NLM136249191
|x 0578-1310
|7 nnns
|
| 773 |
1 |
8 |
|g volume:52
|g year:2014
|g number:2
|g day:16
|g month:02
|g pages:99-102
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_50
|
| 912 |
|
|
|a GBV_ILN_61
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_227
|
| 912 |
|
|
|a GBV_ILN_244
|
| 912 |
|
|
|a GBV_ILN_285
|
| 912 |
|
|
|a GBV_ILN_294
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_665
|
| 912 |
|
|
|a GBV_ILN_813
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 52
|j 2014
|e 2
|b 16
|c 02
|h 99-102
|